Sound Pharmaceuticals Files IND with FDA to Test SPI-1005 in Phase 2 COVID-19 trials
SEATTLE, WASHINGTON — Sound Pharmaceuticals has announced the filing of an Investigational New Drug (IND) Application with the FDA to begin Phase 2 studies to prevent and treat COVID-19 with its investigational drug, SPI-1005. SPI-1005 was recently allowed by the FDA to advance to Phase 3 trials in patient’s with Meniere’s disease and is currently…
Read More
Sound Pharma Advances to Phase 3 Clinical Trials for Meniere’s Disease Drug, SPI-1005
SEATTLE, WASHINGTON — Sound Pharmaceuticals announced today that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). This is the first Phase 3 study of an investigational new drug for the treatment of Meniere’s Disease (MD), a neurotologic disease involving hearing loss, tinnitus,…
Read MoreSound Pharmaceuticals Announces Encouraging Results in Meniere’s Disease Clinical Trial; May Go Public in 2020
SEATTLE, WASHINGTON — Biotech firm, Sound Pharmaceuticals, announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center Phase 2b study in Meniere’s Disease (MD). Evaluating SPI-1005 vs. Placebo in Meniere’s Patients In the study, 149 adult patients with active MD, including a hearing loss at baseline of >30 dB in one of three…
Read More
Sound Pharmaceuticals Advances Phase 2 Clinical Trial in Cystic Fibrosis Patients to Prevent Hearing Loss
SEATTLE, WASHINGTON AND CHARLESTON, SOUTH CAROLINA — Sound Pharmaceuticals, a Seattle-based biotech firm, announced that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with the company’s oral drug, SPI-1005, is aimed to prevent and treat ototoxicity in patients with Cystic Fibrosis undergoing intravenous (IV) tobramycin for the…
Read More
Sound Pharmaceuticals Says Positive Results from Phase 1b Clinical Trial in Meniere’s Disease, Starting Phase 2b
SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has achieved positive topline results from its recently completed Phase 1b SPI-1005-151 clinical trial involving Meniere’s Disease (MD) patients. SPI-1005 is the company’s investigational new drug, which mimics and induces Glutathione Peroxidase (GPx), which has been shown to reduce the swelling or…
Read More
Sound Pharmaceuticals Completes Clinical Trial Enrollment on Meniere’s Drug; GV Invests in Decibel Therapeutics
SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced late last month that it had completed enrollment on its first Ménière’s disease clinical trial. The clinical trial will use SPI-1005, an investigational new drug developed by the company that mimics and induces Glutathione Peroxidase (GPx), which has been shown to reduce the swelling or…
Read More
Foundation Awards Sound Pharmaceuticals $1.6 Million for Prevention and Treatment of Antibiotic-Induced Hearing Loss
SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The CFFT award will support the initial testing of SPI-1005 in people with cystic fibrosis (CF)…
Read MoreSound Pharmaceuticals Hires Two New Executives to Speed Development of Meniere’s Drug
SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has hired two senior executives. Paul Hoskins, appointed to the position of Senior Director of Clinical Operations and G. Michael Wall, appointed to the position of Senior Director of Pharmaceutical Development. The new executives join the company with substantial backgrounds in the pharmaceutical industry. Sound Pharmaceuticals hopes that…
Read More